2023 World Conference on Lung Cancer (Posters)-EP06.02. Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

EP06.02. Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

Pdf Summary

This study aimed to investigate the protein expression of AXL, a receptor kinase involved in cancer growth and metastasis, in patients with advanced non-small cell lung cancer (NSCLC) who experienced disease progression on immune checkpoint inhibitor (ICI)-based therapies. The researchers reviewed immunohistochemistry (IHC) results for AXL and PD-L1 from tissue samples of NSCLC patients. They found that AXL expression was associated with PD-L1 expression in NSCLC, particularly in tumors with high PD-L1 tumor proportion scores (TPS). The majority of the patients included in the analysis had pre-treatment tissue samples. Of those who underwent post-chemotherapy or ICI rebiopsy, 14% showed a change in PD-L1 expression, with two cases resulting in a change from 0% to 1% PD-L1 expression. The study suggests that increased AXL protein expression may indicate a mechanism of resistance to ICIs and could be targeted using agents targeting AXL receptors. The researchers propose that a tissue screening strategy for AXL expression may be optimized by selecting NSCLC samples with positive PD-L1 expression, particularly those with high PD-L1 TPS. This information may help in the development of biomarkers for immuno-oncology and targeted therapies for drug-resistant NSCLC.

Asset Subtitle

Muhammad Awidi

Meta Tag

Speaker Muhammad Awidi

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

protein expression

AXL

receptor kinase

cancer growth

metastasis

NSCLC

immune checkpoint inhibitor

PD-L1

tissue samples

biomarkers